Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in:

Open Access 01-12-2024 | Review

Ferroptosis and the tumor microenvironment

Authors: Kaisa Cui, Kang Wang, Zhaohui Huang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

Ferroptosis is a type of regulated cell death characterized by its non-apoptotic, iron-dependent and oxidative nature. Since its discovery in 2012, extensive research has demonstrated its pivotal roles in tumorigenesis, metastasis and cancer therapy. The tumor microenvironment (TME) is a complex ecosystem comprising cancer cells, non-cancer cells, extracellular matrix, metabolites and cytokines. Recent studies have underscored a new paradigm in which non-cancer cells in the TME, such as immune and stromal cells, also play significant roles in regulating tumor progression and therapeutic resistance typically through complicated crosstalk with cancer cells. Notably, this crosstalk in the TME were partially mediated through ferrotopsis-related mechanisms. This review provides a comprehensive and systematic summary of the current findings concerning the roles of ferroptosis in the TME and how ferroptosis-mediated TME reprogramming impacts cancer therapeutic resistance and progression. Additionally, this review outlines various ferroptosis-related therapeutic strategies aimed at targeting the TME.
Literature
1.
Meier P, Legrand AJ, Adam D, Silke J. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat Rev Cancer. 2024;24(5):299–315.PubMedCrossRef
2.
Galluzzi L, Bravo-San Pedro JM, Vitale I, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 2015;22(1):58–73.PubMedCrossRef
3.
4.
5.
6.
Xie X, Chen C, Wang C, et al. Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors. Redox Biol. 2024;76:103350.PubMedPubMedCentralCrossRef
7.
8.
Yin Y, Liu B, Cao Y, et al. Colorectal Cancer-derived small extracellular vesicles promote Tumor Immune Evasion by upregulating PD-L1 expression in Tumor-Associated macrophages. Adv Sci (Weinh). 2022;9(9):2102620.PubMedCrossRef
9.
Raposo G, Stahl PD. Extracellular vesicles - on the cusp of a new language in the biological sciences. Extracell Vesicles Circ Nucl Acids. 2023;4(2):240–54.PubMedPubMedCentralCrossRef
10.
Asao T, Tobias GC, Lucotti S, Jones DR, Matei I, Lyden D. Extracellular vesicles and particles as mediators of long-range communication in cancer: connecting biological function to clinical applications. Extracell Vesicles Circ Nucl Acids. 2023;4(3):461–85.PubMedPubMedCentralCrossRef
11.
Cao M. The extracellular RNA and drug resistance in cancer: a narrative review. Rev ExRNA. 2023;5(1):0003.
12.
Fakih M, Ouyang C, Wang C, et al. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. J Clin Invest. 2019;129(10):4464–76.PubMedPubMedCentralCrossRef
13.
14.
Cui K, Yao S, Zhang H, et al. Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer. Oncogene. 2021;40(11):2130–45.PubMedCrossRef
15.
Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234–45.PubMedPubMedCentralCrossRef
16.
Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3(3):285–96.PubMedCrossRef
17.
Abe C, Miyazawa T, Miyazawa T. Current use of Fenton reaction in drugs and food. Molecules. 2022;27(17).
18.
19.
Dos Santos AF, Fazeli G, Xavier da Silva TN, Friedmann Angeli JP. Ferroptosis: mechanisms and implications for cancer development and therapy response. Trends Cell Biol. 2023;33(12):1062–76.PubMedCrossRef
20.
Brillas E, Sirés I, Oturan MA. Electro-Fenton process and related electrochemical technologies based on Fenton’s reaction chemistry. Chem Rev. 2009;109(12):6570–631.PubMedCrossRef
21.
22.
23.
Tang Z, Zhao P, Wang H, Liu Y, Bu W. Biomedicine meets Fenton Chemistry. Chem Rev. 2021;121(4):1981–2019.PubMedCrossRef
24.
Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91–8.PubMedCrossRef
25.
Wang K, Zhang Z, Tsai HI, et al. Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells. Cell Death Differ. 2021;28(4):1222–36.PubMedCrossRef
26.
Ursini F, Maiorino M, Valente M, Ferri L, Gregolin C. Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. Biochim Biophys Acta. 1982;710(2):197–211.PubMedCrossRef
27.
28.
29.
Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693–8.PubMedCrossRef
30.
31.
Yang C, Zhao Y, Wang L, et al. De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence. Nat Cell Biol. 2023;25(6):836–47.PubMedCrossRef
32.
Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023;41(3):404–20.PubMedCrossRef
33.
Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92.PubMedCrossRef
34.
Adamo A, Dal Collo G, Bazzoni R, Krampera M. Role of mesenchymal stromal cell-derived extracellular vesicles in tumour microenvironment. Biochim Biophys Acta Rev Cancer. 2019;1871(1):192–8.PubMedCrossRef
35.
Yamamoto Y, Kasashima H, Fukui Y, Tsujio G, Yashiro M, Maeda K. The heterogeneity of cancer-associated fibroblast subpopulations: their origins, biomarkers, and roles in the tumor microenvironment. Cancer Sci. 2023;114(1):16–24.PubMedCrossRef
36.
37.
Foster DS, Januszyk M, Delitto D, et al. Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin. Cancer Cell. 2022;40(11):1392–406. e7.PubMedPubMedCentralCrossRef
38.
Liu F, Tang L, Liu H, et al. Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2. Cell Death Dis. 2024;15(4):279.PubMedPubMedCentralCrossRef
39.
Zhu Y, Fang S, Fan B, et al. Cancer-associated fibroblasts reprogram cysteine metabolism to increase tumor resistance to ferroptosis in pancreatic cancer. Theranostics. 2024;14(4):1683–700.PubMedPubMedCentralCrossRef
40.
Jiang F, Jia K, Chen Y, et al. ANO1-Mediated inhibition of Cancer Ferroptosis confers immunotherapeutic resistance through recruiting Cancer-Associated fibroblasts. Adv Sci (Weinh). 2023;10(24):e2300881.PubMedCrossRef
41.
van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213–28.PubMedCrossRef
42.
Ana Luísa Teixeira FD. Extracellular vesicles from cancer cells are key players of metastatic cell phenotype induction. ExRNA. 2023;2(2):0004.
43.
Qi R, Bai Y, Li K, et al. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resist Updat. 2023;68:100960.PubMedCrossRef
44.
Zhang H, Deng T, Liu R, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19(1):43.PubMedPubMedCentralCrossRef
45.
Zhao J, Shen J, Mao L, Yang T, Liu J, Hongbin S. Cancer associated fibroblast secreted Mir-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer. Oncogene. 2024.
46.
Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2023;23(2):106–20.PubMedCrossRef
47.
48.
49.
Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19(6):402–21.PubMedCrossRef
50.
Wang H, An P, Xie E, et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology. 2017;66(2):449–65.PubMedCrossRef
51.
Luo X, Gong HB, Gao HY, et al. Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ. 2021;28(6):1971–89.PubMedPubMedCentralCrossRef
52.
Luo X, Gong HB, Li ZC, et al. Phospholipid peroxidation in macrophage confers tumor resistance by suppressing phagocytic capability towards ferroptotic cells. Cell Death Differ. 2024;31(9):1184–201.PubMedCrossRef
53.
Wen Q, Liu J, Kang R, Zhou B, Tang D. The release and activity of HMGB1 in ferroptosis. Biochem Biophys Res Commun. 2019;510(2):278–83.PubMedCrossRef
54.
Wan C, Sun Y, Tian Y, et al. Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Sci Adv. 2020;6(13):eaay9789.PubMedPubMedCentralCrossRef
55.
Chen P, Wang D, Xiao T, et al. ACSL4 promotes ferroptosis and M1 macrophage polarization to regulate the tumorigenesis of nasopharyngeal carcinoma. Int Immunopharmacol. 2023;122:110629.PubMedCrossRef
56.
Xiong H, Zhai Y, Meng Y, et al. Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization. Cancer Lett. 2024;587:216732.PubMedCrossRef
57.
Hao X, Zheng Z, Liu H, et al. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 2022;56:102463.PubMedPubMedCentralCrossRef
58.
Li LG, Peng XC, Yu TT, et al. Dihydroartemisinin remodels macrophage into an M1 phenotype via ferroptosis-mediated DNA damage. Front Pharmacol. 2022;13:949835.PubMedPubMedCentralCrossRef
59.
Tang B, Wang Y, Xu W, et al. Macrophage xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer. Cancer Lett. 2023;554:216021.PubMedCrossRef
60.
Tang B, Zhu J, Wang Y, et al. Targeted xCT-mediated ferroptosis and Protumoral polarization of Macrophages is effective against HCC and enhances the efficacy of the Anti-PD-1/L1 response. Adv Sci (Weinh). 2023;10(2):e2203973.PubMedCrossRef
61.
Mu M, Huang CX, Qu C, et al. Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and enhances Sorafenib Efficacy. Cancer Res. 2024;84(6):841–54.PubMedCrossRef
62.
Su W, Gao W, Zhang R, et al. TAK1 deficiency promotes liver injury and tumorigenesis via ferroptosis and macrophage cGAS-STING signalling. JHEP Rep. 2023;5(5):100695.PubMedPubMedCentralCrossRef
63.
Li H, Yang C, Wei Y, et al. Ferritin light chain promotes the reprogramming of glioma immune microenvironment and facilitates glioma progression. Theranostics. 2023;13(11):3794–813.PubMedPubMedCentralCrossRef
64.
Cang W, Wu A, Gu L, et al. Erastin enhances metastatic potential of ferroptosis-resistant ovarian cancer cells by M2 polarization through STAT3/IL-8 axis. Int Immunopharmacol. 2022;113(Pt B):109422.PubMedCrossRef
65.
Li H, Yang P, Wang J, et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J Hematol Oncol. 2022;15(1):2.PubMedPubMedCentralCrossRef
66.
Ma L, Chen C, Zhao C, et al. Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer. Signal Transduct Target Ther. 2024;9(1):64.PubMedPubMedCentralCrossRef
67.
Schwantes A, Wickert A, Becker S, et al. Tumor associated macrophages transfer ceruloplasmin mRNA to fibrosarcoma cells and protect them from ferroptosis. Redox Biol. 2024;71:103093.PubMedPubMedCentralCrossRef
68.
Luo Y, Chen Y, Jin H, et al. The suppression of cervical cancer ferroptosis by macrophages: the attenuation of ALOX15 in cancer cells by macrophages-derived exosomes. Acta Pharm Sin B. 2023;13(6):2645–62.PubMedPubMedCentralCrossRef
69.
Xu L, Li W, Liu D, et al. ANXA3-Rich Exosomes Derived from Tumor-Associated macrophages regulate ferroptosis and lymphatic metastasis of laryngeal squamous cell carcinoma. Cancer Immunol Res. 2024;12(5):614–30.PubMedCrossRef
70.
Yi C, Wu S, Duan Q, et al. Ferroptosis-dependent breast cancer cell-derived exosomes inhibit migration and invasion of breast cancer cells by suppressing M2 macrophage polarization. PeerJ. 2023;11:e15060.PubMedPubMedCentralCrossRef
71.
Dai E, Han L, Liu J, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16(11):2069–83.PubMedPubMedCentralCrossRef
72.
Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022;22(3):173–87.PubMedCrossRef
73.
Knaapen AM, Seiler F, Schilderman PA, et al. Neutrophils cause oxidative DNA damage in alveolar epithelial cells. Free Radic Biol Med. 1999;27(1–2):234–40.PubMedCrossRef
74.
Lu Z, Wang X, Feng J, et al. Intratumoral CXCR4(hi) neutrophils display ferroptotic and immunosuppressive signatures in hepatoblastoma. Front Immunol. 2024;15:1363454.PubMedPubMedCentralCrossRef
75.
Zhao Y, Liu Z, Liu G, et al. Neutrophils resist ferroptosis and promote breast cancer metastasis through aconitate decarboxylase 1. Cell Metab. 2023;35(10):1688–703. e10.PubMedPubMedCentralCrossRef
76.
Wang D, Li X, Jiao D, et al. LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia. J Hematol Oncol. 2023;16(1):30.PubMedPubMedCentralCrossRef
77.
78.
79.
Conche C, Finkelmeier F, Pesic M, et al. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut. 2023;72(9):1774–82.PubMedCrossRef
80.
81.
van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–32.PubMedPubMedCentralCrossRef
82.
Xiao L, Ma X, Ye L et al. IL-9/STAT3/fatty acid oxidation-mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity. J Clin Invest. 2022;132(7).
83.
Ivashkiv LB. IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545–58.PubMedPubMedCentralCrossRef
84.
Li C, Phoon YP, Karlinsey K et al. A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. J Exp Med. 2022;219(1).
85.
Gao Y, Shi H, Zhao H, et al. Single-cell transcriptomics identify TNFRSF1B as a novel T-cell exhaustion marker for ovarian cancer. Clin Transl Med. 2023;13(9):e1416.PubMedPubMedCentralCrossRef
86.
Lee YH, Chuah S, Nguyen PHD, et al. IFNgamma(-)IL-17(+) CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma. Cancer Lett. 2023;552:215977.PubMedCrossRef
87.
88.
Ma X, Xiao L, Liu L, et al. CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33(5):1001–e10125.PubMedPubMedCentralCrossRef
89.
St Paul M, Ohashi PS. The roles of CD8(+) T cell subsets in Antitumor Immunity. Trends Cell Biol. 2020;30(9):695–704.PubMedCrossRef
90.
Lu Y, Hong B, Li H, et al. Tumor-specific IL-9-producing CD8 + Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci U S A. 2014;111(6):2265–70.PubMedPubMedCentralCrossRef
91.
Ma X, Bi E, Huang C, et al. Cholesterol negatively regulates IL-9-producing CD8(+) T cell differentiation and antitumor activity. J Exp Med. 2018;215(6):1555–69.PubMedPubMedCentralCrossRef
92.
Li S, Ouyang X, Sun H, et al. DEPDC5 protects CD8(+) T cells from ferroptosis by limiting mTORC1-mediated purine catabolism. Cell Discov. 2024;10(1):53.PubMedPubMedCentralCrossRef
93.
Morotti M, Grimm AJ, Hope HC, et al. PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. Nature. 2024;629(8011):426–34.PubMedPubMedCentralCrossRef
94.
Han C, Ge M, Xing P, et al. Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8(+) T cells. Cell Death Dis. 2024;15(2):145.PubMedPubMedCentralCrossRef
95.
96.
Lang X, Green MD, Wang W, et al. Radiotherapy and Immunotherapy Promote Tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9(12):1673–85.PubMedPubMedCentralCrossRef
97.
Liao P, Wang W, Wang W, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40(4):365–78. e6.PubMedPubMedCentralCrossRef
98.
Li Y, Hu G, Huang F, et al. MAT1A suppression by the CTBP1/HDAC1/HDAC2 Transcriptional Complex Induces Immune Escape and reduces ferroptosis in Hepatocellular Carcinoma. Lab Invest. 2023;103(8):100180.PubMedCrossRef
99.
Raffin C, Vo LT, Bluestone JA. T(reg) cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20(3):158–72.PubMedCrossRef
100.
Xu C, Sun S, Johnson T, et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 2021;35(11):109235.PubMedCrossRef
101.
Jin D, Hui Y, Liu D, et al. LINC00942 inhibits ferroptosis and induces the immunosuppression of regulatory T cells by recruiting IGF2BP3/SLC7A11 in hepatocellular carcinoma. Funct Integr Genomics. 2024;24(1):29.PubMedPubMedCentralCrossRef
102.
103.
Gong L, Li Y, Cui K, et al. Nanobody-Engineered Natural Killer Cell conjugates for Solid Tumor Adoptive Immunotherapy. Small. 2021;17(45):e2103463.PubMedCrossRef
104.
Cui JX, Xu XH, He T, et al. L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis. J Exp Clin Cancer Res. 2023;42(1):52.PubMedPubMedCentralCrossRef
105.
Yao L, Hou J, Wu X, et al. Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation. Redox Biol. 2023;67:102923.PubMedPubMedCentralCrossRef
106.
Cui K, Gong L, Wang K, et al. Ferroptosis-Associated Molecular features to Aid Patient Clinical Prognosis and Therapy Across Human cancers. Front Immunol. 2022;13:888757.PubMedPubMedCentralCrossRef
107.
Zhou N, Bao J. FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020;2020.
108.
Zhou N, Yuan X, Du Q, et al. FerrDb V2: update of the manually curated database of ferroptosis regulators and ferroptosis-disease associations. Nucleic Acids Res. 2023;51(D1):D571–82.PubMedCrossRef
109.
He Y, Dong Y, Chen Y, et al. Multi-omics characterization and therapeutic liability of ferroptosis in melanoma. Signal Transduct Target Ther. 2022;7(1):268.PubMedPubMedCentralCrossRef
110.
Meng Y, Sun HY, He Y, et al. BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition. Mil Med Res. 2023;10(1):61.PubMedPubMedCentral
111.
Tang B, Yan R, Zhu J, et al. Integrative analysis of the molecular mechanisms, immunological features and immunotherapy response of ferroptosis regulators across 33 cancer types. Int J Biol Sci. 2022;18(1):180–98.PubMedPubMedCentralCrossRef
112.
Han L, Zhou J, Li L, et al. SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma. Cell Death Dis. 2022;13(12):1071.PubMedPubMedCentralCrossRef
113.
Chung CH, Lin CY, Chen CY, et al. Ferroptosis Signature Shapes the Immune profiles to enhance the response to Immune checkpoint inhibitors in Head and Neck Cancer. Adv Sci (Weinh). 2023;10(15):e2204514.PubMedCrossRef
114.
Kciuk M, Gielecinska A, Kaluzinska-Kolat Z, Yahya EB, Kontek R. Ferroptosis and cuproptosis: metal-dependent cell death pathways activated in response to classical chemotherapy - significance for cancer treatment? Biochim Biophys Acta Rev Cancer. 2024;1879(4):189124.PubMedCrossRef
115.
Zhang Y, Shen G, Meng T, et al. Eicosapentaenoic acid enhances the sensitivity of osteosarcoma to cisplatin by inducing ferroptosis through the DNA-PKcs/AKT/NRF2 pathway and reducing PD-L1 expression to attenuate immune evasion. Int Immunopharmacol. 2023;125Pt B:111181.CrossRef
116.
Zhou Z, Zhao Y, Chen S, et al. Cisplatin promotes the efficacy of Immune checkpoint inhibitor therapy by inducing ferroptosis and activating neutrophils. Front Pharmacol. 2022;13:870178.PubMedPubMedCentralCrossRef
117.
Zheng Y, Wang Y, Lu Z, et al. PGAM1 inhibition promotes HCC Ferroptosis and synergizes with Anti-PD-1 Immunotherapy. Adv Sci (Weinh). 2023;10(29):e2301928.PubMedCrossRef
118.
Wang Z, Li R, Hou N et al. PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis. J Immunother Cancer. 2023;11(6).
119.
Hsieh MS, Ling HH, Setiawan SA, et al. Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer. Chem Biol Interact. 2024;395:111004.PubMedCrossRef
120.
Viswanadhapalli S, Luo Y, Sareddy GR, et al. EC359: a first-in-class small-molecule inhibitor for Targeting Oncogenic LIFR Signaling in Triple-negative breast Cancer. Mol Cancer Ther. 2019;18(8):1341–54.PubMedCrossRef
121.
Ebrahimi B, Viswanadhapalli S, Pratap UP, et al. Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis. NPJ Precis Oncol. 2024;8(1):118.PubMedPubMedCentralCrossRef
122.
Cheu JW, Lee D, Li Q, et al. Ferroptosis Suppressor Protein 1 inhibition promotes Tumor Ferroptosis and Anti-tumor Immune responses in Liver Cancer. Cell Mol Gastroenterol Hepatol. 2023;16(1):133–59.PubMedPubMedCentralCrossRef
123.
Wang H, Zhang H, Chen Y et al. Targeting Wnt/beta-Catenin signaling exacerbates ferroptosis and increases the efficacy of Melanoma Immunotherapy via the regulation of MITF. Cells. 2022;11(22).
124.
Fan F, Liu P, Bao R, et al. A dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to Potentiate Cancer Immune Checkpoint Therapy. Cancer Res. 2021;81(24):6233–45.PubMedCrossRef
125.
Li J, Liu J, Zhou Z, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15(720):eadg3049.PubMedCrossRef
126.
Fan R, Deng A, Lin R, et al. A platinum(IV)-artesunate complex triggers ferroptosis by boosting cytoplasmic and mitochondrial lipid peroxidation to enhance tumor immunotherapy. MedComm (2020). 2024;5(6):e570.PubMedCrossRef
127.
128.
Lei G, Zhang Y, Koppula P, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020;30(2):146–62.PubMedPubMedCentralCrossRef
129.
Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted alpha-particle radiation therapy. Clin Cancer Res. 2013;19(3):530–7.PubMedCrossRef
130.
Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett. 2012;327(1–2):48–60.PubMedCrossRef
131.
Ding X, Cheng J, Pang Q, et al. BIBR1532, a selective telomerase inhibitor, enhances radiosensitivity of Non-small Cell Lung Cancer through increasing Telomere Dysfunction and ATM/CHK1 inhibition. Int J Radiat Oncol Biol Phys. 2019;105(4):861–74.PubMedCrossRef
132.
Bao Y, Pan Z, Zhao L, et al. BIBR1532 combined with radiotherapy induces ferroptosis in NSCLC cells and activates cGAS-STING pathway to promote anti-tumor immunity. J Transl Med. 2024;22(1):519.PubMedPubMedCentralCrossRef
133.
Deng Z, Li B, Yang M, et al. Irradiated microparticles suppress prostate cancer by tumor microenvironment reprogramming and ferroptosis. J Nanobiotechnol. 2024;22(1):225.CrossRef
134.
Huang X, He T, Liang X, et al. Advances and applications of nanoparticles in cancer therapy. MedComm – Oncol. 2024;3(1):e67.CrossRef
135.
Chen Y, Gong L, Cao Y, et al. Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer. J Control Release. 2024;366:395–409.PubMedCrossRef
136.
Gong L, Tian L, Cui K, et al. An off-the-shelf small extracellular vesicle nanomedicine for tumor targeting therapy. J Control Release. 2023;364:672–86.PubMedCrossRef
137.
Li D, Gong L, Lin H, et al. Hyaluronic acid-coated bovine milk exosomes for achieving tumor-specific intracellular delivery of miRNA-204. Cells. 2022;11:19.
138.
Liu Y, Lu R, Li M, et al. Dual-enzyme decorated semiconducting polymer nanoagents for second near-infrared photoactivatable ferroptosis-immunotherapy. Mater Horiz. 2024;11(10):2406–19.PubMedCrossRef
139.
Wang S, Guo Q, Xu R, Lin P, Deng G, Xia X. Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma. J Nanobiotechnol. 2023;21(1):383.CrossRef
140.
Ruan Y, Zhuang H, Zeng X, et al. Engineered Microbial nanohybrids for Tumor-mediated NIR II Photothermal enhanced Ferroptosis/Cuproptosis and immunotherapy. Adv Healthc Mater. 2024;13(4):e2302537.PubMedCrossRef
141.
Lei H, Li Q, Pei Z, Liu L, Yang N, Cheng L. Nonferrous Ferroptosis Inducer Manganese Molybdate nanoparticles to enhance Tumor Immunotherapy. Small. 2023;19(45):e2303438.PubMedCrossRef
142.
Deng X, Liu T, Zhu Y, et al. Ca & mn dual-ion hybrid nanostimulator boosting anti-tumor immunity via ferroptosis and innate immunity awakening. Bioact Mater. 2024;33:483–96.PubMed
143.
Song H, Sun H, He N, et al. Glutathione Depletion-Induced Versatile Nanomedicine for potentiating the ferroptosis to overcome solid Tumor Radioresistance and enhance immunotherapy. Adv Healthc Mater. 2024;13(9):e2303412.PubMedCrossRef
144.
Fan Z, Wu S, Deng H, Li G, Huang L, Liu H. Light-triggered nanozymes remodel the Tumor Hypoxic and Immunosuppressive Microenvironment for ferroptosis-enhanced Antitumor Immunity. ACS Nano. 2024;18(19):12261–75.PubMedCrossRef
145.
Wang H, Jiao D, Feng D, et al. Transformable Supramolecular Self-assembled peptides for Cascade Self-enhanced ferroptosis primed Cancer Immunotherapy. Adv Mater. 2024;36(21):e2311733.PubMedCrossRef
146.
Liu J, Zhan J, Zhang Y, et al. Ultrathin clay nanoparticles-mediated mutual reinforcement of ferroptosis and Cancer immunotherapy. Adv Mater. 2024;36(9):e2309562.PubMedCrossRef
147.
Lei H, Li Q, Li G, et al. Manganese molybdate nanodots with dual amplification of STING activation for cycle treatment of metalloimmunotherapy. Bioact Mater. 2024;31:53–62.PubMed
148.
Wu Q, Li Z, Zhou X, et al. Photothermal Ferrotherapy - Induced Immunogenic Cell Death via Iron-based Ternary Chalcogenide nanoparticles against Triple-negative breast Cancer. Small. 2024;20(20):e2306766.PubMedCrossRef
149.
Zhang L, Qiu M, Wang R, et al. Monitoring ROS Responsive Fe(3)O(4)-based Nanoparticle Mediated Ferroptosis and immunotherapy via (129)Xe MRI. Angew Chem Int Ed Engl. 2024;63(22):e202403771.PubMedCrossRef
150.
Feng Q, Fang W, Guo Y, Hu P, Shi J. Nebulized therapy of early orthotopic Lung Cancer by Iron-based nanoparticles: macrophage-regulated ferroptosis of Cancer Stem cells. J Am Chem Soc. 2023;145(44):24153–65.PubMedCrossRef
151.
Wang Y, Xu H, Wang D, et al. Synergistic reinforcement of immunogenic cell death and transformation of tumor-associated macrophages via an M1-type macrophage membrane-camouflaged ferrous-supply-regeneration nanoplatform. Acta Biomater. 2024;174:358–71.PubMedCrossRef
Metadata
Title
Ferroptosis and the tumor microenvironment
Authors
Kaisa Cui
Kang Wang
Zhaohui Huang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-024-03235-0

Other articles of this Issue 1/2024

METTL3 recruiting M2-type immunosuppressed macrophages by targeting m6A-SNAIL-CXCL2 axis to promote colorectal cancer pulmonary metastasis

Hepatocyte-derived Igκ promotes HCC progression by stabilizing electron transfer flavoprotein subunit α to facilitate fatty acid β-oxidation

N6-methyladenosine modification of circMARK2 enhances cytoplasmic export and stabilizes LIN28B, contributing to the progression of Wilms tumor

Gli1-mediated tumor cell-derived bFGF promotes tumor angiogenesis and pericyte coverage in non-small cell lung cancer

  • Open Access
  • NSCLC
  • Research

PRMT6-mediated transcriptional activation of ythdf2 promotes glioblastoma migration, invasion, and emt via the wnt–β-catenin pathway

The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits